Holen Sie sich die Stockscreener-App
15.82
4.32%
0.65
Schlusskurs vom Vortag:
$15.17
Offen:
$15.3
24-Stunden-Volumen:
760.36K
Relative Volume:
0.52
Marktkapitalisierung:
$1.33B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.17M
KGV:
-30.08
EPS:
-0.526
Netto-Cashflow:
$-35.14M
1W Leistung:
+5.92%
1M Leistung:
+42.31%
6M Leistung:
+122.89%
1J Leistung:
+305.77%
1-Tages-Spanne:
$14.93
$15.87
1-Wochen-Bereich:
$14.58
$15.87
52-Wochen-Spanne:
$3.86
$26.95
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Firmenname
Corvus Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 900-4520
Adresse
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA
Compare CRVS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
15.82 | 1.28B | 0 | -44.17M | -35.14M | -0.526 |
VRTX
Vertex Pharmaceuticals Inc
|
523.88 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.87 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.67 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.22 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.59 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-17 | Eingeleitet | Goldman | Buy |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-01-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-18 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-05-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-02-10 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-05-29 | Eingeleitet | ROTH Capital | Buy |
| 2017-08-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | Eingeleitet | Credit Suisse | Outperform |
| 2016-04-18 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten
Corvus Pharmaceuticals (CRVS) Stock Analysis Report | Financials & Insights - Benzinga España
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits
Is Corvus Pharmaceuticals (CRVS) Still Undervalued After Its Share Price Jump? - Sahm
Corvus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:CRVS) - TradingView
Corvus Pharmaceuticals, Inc. Actuals & Estimates (BX:C17) - TradingView
Corvus Pharmaceuticals, Inc. Actuals & Estimates (SWB:C17) - TradingView
Corvus Pharmaceuticals, Inc. Actuals & Estimates (DUS:C17) - TradingView
CRVS Forecast — Price Target — Prediction for 2027 - TradingView
Corvus Pharmaceuticals (CRVS) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Price to book forward of Corvus Pharmaceuticals, Inc. – NASDAQ:CRVS - TradingView
Price to sales forward of Corvus Pharmaceuticals, Inc. – NASDAQ:CRVS - TradingView
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy? - Yahoo Finance
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy? - The Motley Fool
Corvus Pharmaceuticals Inc (CRVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Institutional Confidence - TradingKey
Insider Buys Additional US$250k In Corvus Pharmaceuticals Stock - simplywall.st
Corvus Pharmaceuticals Inc (CRVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Corvus CEO thinks his next blockbuster is an ITK inhibitor - Pharma Voice
Corvus Pharmaceuticals (CRVS) director buys 21,700 shares and receives 15,000-share option - Stock Titan
[Form 4] Corvus Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Corvus Pharmaceuticals (CRVS) director receives grant of 15,000 stock options - Stock Titan
Director at Corvus (CRVS) receives grant of 15,000 stock options - Stock Titan
Corvus (CRVS) director awarded options for 15,000 shares at $11.60 - Stock Titan
Corvus Pharmaceuticals Faces Key Soquelitinib Data And Possible M&A Interest - Yahoo Finance
Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now? - Insider Monkey
Corvus Stockholders Approve Directors and Governance Proposals - TipRanks
Corvus Pharmaceuticals (CRVS) posts 2026 annual shareholder meeting voting outcomes - Stock Titan
Corvus Hikes on Position in Angel - Baystreet.ca
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China - The Manila Times
$13.5M bet on soquelitinib: China eczema and asthma trials move ahead - Stock Titan
Corvus Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
CRVS: Soquelitinib progresses in pivotal trials for PTCL and AD, targeting broad immunology markets - TradingView
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Corvus drops after early-stage trial data for eczema therapy - MSN
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Strong One Year Gains And Recent Share Price Weakness - simplywall.st
CRVSCorvus Pharmaceuticals Inc Latest SEC Filings - Finviz
Corvus Pharmaceuticals to present at major healthcare conferences in June 2026 - Pluang
Corvus (CRVS) CEO adds 6,932 shares via Miller-Horning family trust - Stock Titan
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference - marketscreener.com
Biotech Corvus heads to Jefferies and Goldman Sachs health conferences - Stock Titan
Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early (CRVS) - Seeking Alpha
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst CallSlideshow (NASDAQ:CRVS) 2026-05-18 - Seeking Alpha
Finanzdaten der Corvus Pharmaceuticals Inc-Aktie (CRVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Corvus Pharmaceuticals Inc-Aktie (CRVS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MILLER RICHARD A MD | President and CEO |
May 18 '26 |
Buy |
12.04 |
6,932 |
83,453 |
1,195,035 |
| Thompson Peter A. | Director |
Jan 28 '26 |
Option Exercise |
5.33 |
210,000 |
1,119,374 |
210,000 |
2.18%
2.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):